Marks: CAR T cancer risk is acceptable, at least for oncology applications

The risk of secondary malignancies from CAR T cells that shook cell therapy developers late last year shouldn’t derail CAR T development for cancer, according to CBER Director Peter Marks, but the fate of other CAR T cell applications is up for debate.

During the Alliance for Regenerative Medicine (ARM) Cell & Gene Therapy State of the Industry briefing at the J.P. Morgan Healthcare Conference on Monday, Marks provided an update on the incidence of the serious adverse events...